Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
SALT LAKE CITY, Nov. 21, 2016 -- Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, will present at the upcoming 28th Annual Piper Jaffray Healthcare Conference. Dr. Critchfield’s presentation will take place at 11:30 AM ET on Tuesday, November 29th, at the Lotte New York Palace in New York.
Sera Prognostics management will be participating in one-on-one meetings with conference attendees during the day.
About Sera Prognostics, Inc.
Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s proprietary technology addresses both the health and economic challenges of PTB. Its strong management team has significant clinical development and women's healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, and the Bill & Melinda Gates Foundation. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into alternative technologies ideal for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company's website at www.seraprognostics.com.
Company Contact: Andrew Sauter Sera Prognostics [email protected] (801) 990-0772 Media Contact Terri Clevenger Continuum Health Communications [email protected] (203) 856-4326
